Key facts
- This page summarizes Bryan M. Reasons's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 05 Jun 2023, 16:57.
Bryan M. Reasons - 01 Jun 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)
- Reporting relationship
- Director
- Issuer ticker
- ACRS
- Reported as of
- 01 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2023, 16:57:56 UTC
- Prior SEC filing
- 19 May 2023
- Next SEC filing
- 05 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bryan M. Reasons filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 05 Jun 2023.
Change
- Previous filing in this sequence was filed on 19 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,507
- Change %
- +23%
- Price
- Shares after
- 24,072
- Date
- 02 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,750
- Change %
- Price
- $0.000000
- Shares after
- 15,750
- Date
- 01 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,750
- Exercise price
- $8.70
- Footnotes
- F2, F3
ACRS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +4,660
- Change %
- Price
- $0.000000
- Shares after
- 4,660
- Date
- 01 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,660
- Exercise price
- Footnotes
- F1, F2, F4
ACRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,507
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,507
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Footnote F2
This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
Footnote F3
The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date.
Footnote F4
The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date.
Footnote F5
The shares underlying these restricted stock units vested on June 2, 2023.